• 1
    Alexanian, R., Barlogie, B., Tucker, S. (1990) VAD-based regimens as primary treatment for multiple myeloma. American Journal of Hematology, 33, 86 89.
  • 2
    Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484 489.
  • 3
    Alexanian, R., Dimopoulos, M.A., Delasalle, K., Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887 890.
  • 4
    Al-Katib, A., Mohammad, R., Hamdan, M., Mohamed, A.N., Dan, M., Smith, M.R. (1993) Propagation of Waldenstrom's macroglobulinemia cells in vitro and in SCID mice: utility as a preclinical drug screening model. Blood, 81, 3034 3042.
  • 5
    Anderson, K.C., Jones, R.M., Morimoto, C., Leavitt, P., Barut, B.A. (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73, 1915 1924.
  • 6
    Attal, M., Harousseau, J-L., Stoppa, A-M., Sotto, J-J., Fuzibet, J-G., Rossi, J-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91 97.
  • 7
    Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J-F., Lavabre-Bertrand, T., Beck, T., Widjenes, J., Brochier, J., Klein, B. (1995) Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685 691.
  • 8
    Bergsagel, D.E. (1989) Is aggressive chemotherapy more effective in treatment of plasma cell myeloma? European Journal of Haematology, Suppl. 51, 117 123.
  • 9
    Chen, Y-H., Desai, P., Shiao, R-T., Lavelle, D., Haleem, A., Chen, J. (1996) Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood, 87, 314 323.
  • 10
    Cheng, A-L., Su, I., Chen, C-C., Tien, H-F., Lay, J-D., Chen, B-R., Pu, Y-S., Hong, R-Y., Shen, M-C., Wang, C-H., Chen, Y-G. (1994) Use of retinoic acids in the treatment of peripheral T cell lymphoma: a pilot study. Journal of Clinical Oncology, 12, 1185 1192.
  • 11
    Chomczynski, P. & Sacchi, N. (1987) Single-step method of RNA isolation by acid–guanidinium–thiocyanate–phenol–chloroform extraction. Analytical Biochemistry, 162, 156 159.
  • 12
    Demartis, A., Bernassola, F., Savino, R., Melino, G., Ciliberto, G. (1996) Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Research, 56, 4213 4218.
  • 13
    Fried, J., Perez, C., Clarkson, B. (1978) Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Journal of Histochemistry and Cytochemistry, 26, 921 933.
  • 14
    Gharton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., Lowenberg, B., Nikoskelainen, J., Reiffers, J.J., Samson, D., Verdonck, L., Volin, L. (1991) Allogeneic bone marrow transplantation in multiple myeloma. New England Journal of Medicine, 325, 1267 1273.
  • 15
    Gregory, W.M., Richards, M.A., Malpas, J.A. (1992) Combination chemotherapy vs melphalan–prednisone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology, 10, 334 342.
  • 16
    Hansen, M.B., Nielson, S.E., Berg, K. (1989) Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunologic Methods, 119, 203 210.
  • 17
    Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., Epstein, J. (1994) IL-6 prevents dexamethasone-induced myeloma cell death. Blood, 84, 3063 3070.
  • 18
    Hermann, F., Andreef, M., Gruss, H.J., Brach, M.A., Lubbert, M., Mertelsmann, R. (1991) Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood, 78, 2070 2074.
  • 19
    Jean, L-F., Waters, C.A., Keemy, K., Murphy, J.R. (1993) Site-directed and deletion mutational analysis of the receptor binding domain of the interleukin-6 receptor targeted fusion toxin DAB389-IL-6 . Protein Engineering, 6, 305 311.
  • 20
    Jernberg-Wiklund, H., Pettersson, M., Carlsson, M., Nilsson, K. (1992) Increase in IL-6 and IL-6 receptor expression in a human myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia, 6, 310 321.
  • 21
    Joseph, B., Lefebvre, O., Méreau-Richard, C., Danze, P-M., Belin-Plancot, M-T., Formstecher, P. (1998) Evidence for the involvement of both retinoic acid receptor- and retinoic X receptor-dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RPMI 8226. Blood, 91, 2423 2432.
  • 22
    Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83 85.
  • 23
    Kawano, M.M., Mihard, K., Huang, N., Tsujimoto, T., Kuramoto, A. (1995) Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood, 85, 487 494.
  • 24
    Klein, B. (1995) Cytokine, cytokine receptors, transduction signals and oncogenes in human multiple myeloma. Seminars in Hematology, 32, 4 19.
  • 25
    Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood, 73, 517 526.
  • 26
    Kreitman, R.H., Siegall, C.B., FitzGerald, D.J.P., Epstein, J., Barlogie, B., Pastan, I. (1992) Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood, 79, 1775 1780.
  • 27
    Levy, Y., Labaume, S., Colombel, M., Brouet, J.C. (1996) Retinoic acid modulates the in vivo and in vitro growth IL-6 autocrine human myeloma cell lines via induction of apoptosis. Clinical and Experimental Immunology, 104, 167 172.
  • 28
    Levy, Y., Tsapis, A., Brouet, J.C. (1991) Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. Journal of Clinical Investigation, 88, 696 699.
  • 29
    Lokhorst, H.M., Lamme, T., DeSmet, M., Klein, S., DeWeger, R.A., VanOers, R., Bloem, A.C. (1994) Primary tumor cell of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood, 84, 2269 2277.
  • 30
    Lu, Z.Y., Brochier, J., Wijdenes, J., Brailly, H., Bataille, R., Klein, B. (1992) High amounts of circulating IL-6 in the form of monomeric immune complexes during anti-IL-6 therapy. European Journal of Immunology, 22, 2819 2824.
  • 31
    Lutzky, J., Vujicic, M., Yamanashi, D.T., Bhalla, K. (1993) Antiproliferative effects of ATRA and 9-cis-RA on human lymphoid cell lines. Proceedings of the American Association for Cancer Research, 34, 1738A.
  • 32
    Muindi, J., Frankel, S.R., Miller, W.H., Jr. , Jakubowski, A., Scheinberg, D.A., Young, C.W., Dmitrovsky, E., Warrell, R.P. (1992) Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma concentrations: implications for relapse and retinoid ‘resistance’ in patients with acute promyelocytic leukemia. Blood, 79, 299 303.
  • 33
    Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T., Kishimoto, T. (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science, 260, 1808 1810.
  • 34
    Musto, P., Fallone, A., Sajeva, M.R., D'Arena, G., Bonini, A., Carotenuto, M. (1995) All-trans retinoic acid for advanced multiple myeloma. Blood, 85, 3769 3770.
  • 35
    Niesvizky, R., Siege, D.S., Busquets, X., Nichols, G., Muindi, Jr , Warrell, R.P., Jr , Michaeli, J. (1995) Hypercalcaemia and increased serum interleukin-6 levels induced by ATRA in patients with multiple myeloma. British Journal of Haematology, 89, 217 218.
  • 36
    Ogata, A., Nishimoto, N., Shima, Y., Yoshizaki, K., Kishimoto, T. (1994) Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with IL-6 signal transduction. Blood, 84, 3040 3046.
  • 37
    Ray, A., LaForge, S., Sehgal, P.B. (1990) On the mechanism for efficient repression of the IL-6 promoter by glucocorticoids. Molecular and Cellular Biology, 10, 5736 5740.
  • 38
    Schwab, G., Siegall, C.B., Aarden, L.A., Neckers, L.M., Nordan, R.P. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood, 77, 587 593.
  • 39
    Sidell, N., Taga, T., Hirano, T., Kishimoto, T., Saxon, A. (1991) Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. Journal of Immunology, 146, 3809 3814.
  • 40
    Spets, H., Jernberg-Wiklund, H., Sambade, C., Soderberg, O., Nillson, K. (1997) The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. British Journal of Haematology, 98, 126 133.
  • 41
    Sporeno, E., Savino, R., Ciapponi, L., Paonessa, G., Cabibbo, A., Lahm, A., Pulkki, K., Sun, R-X., Toniatti, C., Klein, B., Ciliberto, G. (1996) Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood, 87, 4510 4519.
  • 42
    Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Kishimoto, T. (1992) Anti-human IL-6 receptor antibody inhibits human myeloma cell growth in vivo. European Journal of Immunology, 22, 1889 1923.
  • 43
    Taetle, R., Dos Santos, B., Akamatsu, J-I., Koishihara, Y., Ohsugi, Y. (1996) Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells. Clinical Cancer Research, 2, 253 259.
  • 44
    Taetle, R., Dos Santos, B., Ohsugi, Y., Koishihara, Y., Messner, H., Dalton, W. (1994) Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma. Journal of the National Cancer Institute, 86, 450 455.
  • 45
    Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., Kishimoto, T. (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573 581.
  • 46
    Taga, T., Narazaki, M., Yasukawa, K., Saito, T., Miki, D., Hamaguchi, M., Davis,, S., Shoyab, M., Yancopoulos, G.D., Kishimoto, T. (1992) Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin-6 signal transducer gp130. Proceedings of the National Academy of Sciences of the United States of America, 89, 10998 11001.
  • 47
    Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D., Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cell stimulates interleukin-6 secretion. Blood, 82, 3712 3720.
  • 48
    Urashima, M., Teoh, G., Chauhan, D., Hoshi, Y., Ogata, A., Treon, S.P., Schlossman, R.L., Anderson, K.C. (1997) Interleukin 6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood, 90, 279 289.
  • 49
    Vesole, D., Kornbluth, J., Jagannath, S., Sznol, M., Mattox, S., Vaught, L., Tricot, G., Barlogie, B. (1993) Biological response modifiers in refractory MM: lack of clinical efficacy of rhIL-4 and ATRA. Blood, 82, (Suppl. 1), 1037A.
  • 50
    Vesole, D.H., Jagannath, S., Tricot, G., Desikan, K.R., Siegel, D., Barlogie, B. (1996) Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. Cancer Investigation, 14, 378 391.
  • 51
    Zhang, X.G., Klein, B., Bataille, R. (1989) Interleukin-6 is a potent myeloma-cell growth factor in patients with multiple myeloma. Blood, 7, 11 13.